RESUMEN
Investment, collaboration, and coordination have been key.
Asunto(s)
Investigación Biomédica , COVID-19 , Humanos , Investigación Biomédica/economía , Investigación Biomédica/tendencias , COVID-19/prevención & control , COVID-19/terapia , National Institutes of Health (U.S.) , Inversiones en Salud , Cooperación Internacional , Vacunas contra la COVID-19 , Ensayos Clínicos como AsuntoAsunto(s)
Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/prevención & control , Colaboración Intersectorial , Pandemias/prevención & control , Neumonía Viral/tratamiento farmacológico , Neumonía Viral/prevención & control , Vacunas Virales , Betacoronavirus , COVID-19 , Vacunas contra la COVID-19 , Industria Farmacéutica , Humanos , National Institutes of Health (U.S.) , SARS-CoV-2 , Factores de Tiempo , Estados Unidos , United States Food and Drug Administration , Tratamiento Farmacológico de COVID-19RESUMEN
Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate. R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet these criteria and to be suitable for high compliance oral treatment of HIV-1 infection. The discovery of R278474 was the result of a coordinated multidisciplinary effort involving medicinal chemists, virologists, crystallographers, molecular modelers, toxicologists, analytical chemists, pharmacists, and many others.